LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING. Mediterr J Hematol Infect Dis [Internet]. 2021 Oct. 29 [cited 2026 Jun. 6];13(1):e2021065. Available from: https://www.mjhid.org/mjhid/article/view/4720